ACC2-IN-1
ACC2-IN-1 is an orally active, selective inhibitor of acetyl-CoA carboxylase 2 (ACC2), with an IC50 of 1.9 nM against human targets. ACC2-IN-1 acts as a reducing agent to decrease malonyl-CoA levels in skeletal muscle and exhibits a favorable CYP450 inhibition profile. ACC2-IN-1 can be used in the research of type 2 diabetes.
For research use only. We do not sell to patients.
- CAS No.: 2237229-78-4
- Formula: C20H20ClN3O3S
- Molecular Weight:417.91
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
[1]|
CYP2C19 18 μM (IC50) |
CYP2C9 13 μM (IC50) |
In Vitro
ACC2-IN-1 (compound 2e) potently inhibits human ACC2 with an IC50 of 1.9 nM and is 1026-fold selective over human ACC1[1].
ACC2-IN-1 (30 min) exhibits high metabolic stability, with 91% and 100% remaining after incubation in human and rat liver microsomes, respectively[1].
ACC2-IN-1 has an acceptable CYP450 inhibition profile, with no inhibition of CYP1A2, CYP2D6, or CYP3A4 at concentrations up to 20 μM, and IC50 values of 18 μM for CYP2C19 and 13 μM for CYP2C9[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6[1]
-
Dosage:1.0 mg/kg; 2.5 mg/kg
-
Administration:p.o.; single dose
-
Result:Reduced skeletal muscle malonyl-CoA levels by 20%.
Reduced skeletal muscle malonyl-CoA levels by 41%.
Achieved corresponding plasma drug levels of 1130 ng/mL and 2621 ng/mL for the 1.0 mg/kg and 2.5 mg/kg doses, respectively.
Chemical Information
-
CAS No. 2237229-78-4
-
Molecular Weight 417.91
-
Formula C20H20ClN3O3S
-
SMILES
ClC1=C2C(N=C(S2)OCC)=CC=C1OC3=CC=C(C=N3)/C=C/[C@H](C)NC(C)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
ACC2-IN-1 Related Classifications
HY-183919 Related Classifications
Powered by Bioz